M HOLDINGS LLC NPI 1043858996

NPI Details

M HOLDINGS LLC is a pharmacy in Lexington, SC. The provider is a facility used by pharmacists for the compounding and dispensing of medicinal preparations and other associated professional and administrative services. A pharmacy is a facility whose primary function is to store, prepare and legally dispense prescription drugs under the professional supervision of a licensed pharmacist. It meets any licensing or certification standards set forth by the jurisdiction where it is located. M HOLDINGS LLC NPI is 1043858996. The provider is registered as an organization entity type.
The provider Is Doing Business As My Pharmacy.

The provider's business location address is:

808 HIGHWAY 378 STE A
LEXINGTON, SC
ZIP 29072-379
Phone: (803) 467-4350

The provider's authorized official is James Hampton Manning .
The authorized official title is Owner and has the following contact phone number (803) 756-3460.

The CLIA number assigned to this NPI record is 42D2188916 - pharmacy with a certificate type of Certificate of Waiver.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Covid-19 vaccine administration inside a patient's home; reported only once per individual home per date of service when only covid-19 vaccine administration is performed at the patient's home (HCPCS:M0201)
• Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source (HCPCS:G2023)
• Detection test by immunoassay with direct visual observation for influenza virus (HCPCS:87804)
• Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) (HCPCS:87811)
• Fee covid-19 vac 14 res (HCPCS:0134A)
• Respiratory infectious agent detection by rna for severe acute respiratory syndrome coronavirus 2 (covid 19), influenza a, influenza b, and respiratory syncytial virus, upper respiratory specimen, each reported as detected or not detected (HCPCS:0241U)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Adm sarscov2 50mcg/0.25mlbst (HCPCS:0064A)
• 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r (HCPCS:U0004)
• Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within (HCPCS:U0005)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)
• Fee covid-19 vac 13 res (HCPCS:0124A)
• Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19), influenza virus types a and b, and respiratory syncytial virus (HCPCS:87637)
• Adm sarscv2 30mcg trs-sucr b (HCPCS:0054A)
• Adm sarscov2 30mcg/0.3ml bst (HCPCS:0004A)
• Adm sarscv2 30mcg trs-sucr 1 (HCPCS:0051A)
• Adm sarscov2 100mcg/0.5ml3rd (HCPCS:0013A)
• Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19) and influenza virus types a and b (HCPCS:87636)
• Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free (HCPCS:90674)
• Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza (HCPCS:87428)
• Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, mrna-lnp, spike protein, preservative free, 100 mcg/0.5ml dosage; first dose (HCPCS:0011A)
• Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus (HCPCS:87426)
• Adm sarscv2 30mcg trs-sucr 3 (HCPCS:0053A)
• Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, mrna-lnp, spike protein, preservative free, 100 mcg/0.5ml dosage; second dose (HCPCS:0012A)
• Administration of pneumococcal vaccine (HCPCS:G0009)
• Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use (HCPCS:90677)
• Adm sarscov2 30mcg/0.3ml 3rd (HCPCS:0003A)
• Respiratory infectious agent detection by rna for severe acute respiratory syndrome coronavirus 2 (covid-19), influenza a, and influenza b) in upper respiratory specimen, each reported as detected or not detected (HCPCS:0240U)
• Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, dna, spike protein, adenovirus type 26 (ad26) vector, preservative free, 5x1010 viral particles/0.5ml dosage, single dose (HCPCS:0031A)
• Adm sarscv2 30mcg trs-sucr 2 (HCPCS:0052A)
• Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, mrna-lnp, spike protein, preservative free, 30 mcg/0.3ml dosage, diluent reconstituted; first dose (HCPCS:0001A)

The enumeration date for this NPI number is 12/11/2019 and was last updated on 3/18/2022.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: